Orphanet Journal of Rare Diseases (Oct 2018)

Adult Niemann-Pick disease type C in France: clinical phenotypes and long-term miglustat treatment effect

  • Yann Nadjar,
  • Ana Lucia Hütter-Moncada,
  • Philippe Latour,
  • Xavier Ayrignac,
  • Elsa Kaphan,
  • Christine Tranchant,
  • Pascal Cintas,
  • Adrian Degardin,
  • Cyril Goizet,
  • Chloe Laurencin,
  • Lionel Martzolff,
  • Caroline Tilikete,
  • Mathieu Anheim,
  • Bertrand Audoin,
  • Vincent Deramecourt,
  • Thierry Dubard De Gaillarbois,
  • Emmanuel Roze,
  • Foudil Lamari,
  • Marie T. Vanier,
  • Bénédicte Héron

DOI
https://doi.org/10.1186/s13023-018-0913-4
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Background Niemann-Pick disease type C (NP-C) is a neurodegenerative lysosomal lipid storage disease caused by autosomal recessive mutations in the NPC1 or NPC2 genes. The clinical presentation and evolution of NP-C and the effect of miglustat treatment are described in the largest cohort of patients with adolescent/adult-onset NP-C studied to date. Methods Observational study based on clinical chart data from adult patients with NP-C (> 18 year old) diagnosed in France between 1990 and 2015. Retrospective data from patients at diagnosis, onset of miglustat therapy (if applicable), and last follow up were analysed. Results In France, patients with an adolescent-adult neurological form constituted approximately 25% of all NP-C cases diagnosed during the study period. Forty-seven patients (46 with NP-C1 and one with NP-C2; 53% female) were included. Mean ± SD (range) ages at neurological onset and diagnosis were 23.9 ± 12.5 (8–56) years and 34 ± 13.5 (15–65) years, respectively. At presentation, patients mainly had 1) impaired gait due to cerebellar ataxia and/or dystonia, 2) and/or cognitive/behavioural manifestations, 3) and/or psychotic signs. Initially, almost half of patients had only one of the above three neuro-psychiatric manifestations. Vertical supranuclear gaze palsy, usually occurring without patient complaint, was only detected on careful clinical examination and was recorded in most patients (93%) at the time of diagnosis, several years after neurological onset. Thirty-seven patients (79%) received miglustat, among whom seventeen (46%) continued beyond 2 years (at last follow up) to a maximum of 9.8 years. Eight patients (22%) discontinued treatment early due to side effects (n = 3) or perceived lack of efficacy (n = 5).Miglustat treatment duration correlated significantly with reduced neurological worsening (p < 0.001). Treatment for≥2 years was associated with improved patient survival (p = 0.029). Good responses to miglustat were associated with less severe neurological disability at the start of miglustat treatment (p = 0.02). Conclusion The proportion of adolescent/adult-onset NP-C cases diagnosed in France increased 2.5-fold since 2009 compared with the 2000–2008 period due to improved awareness. Adolescent/adult-onset NP-C frequently presented initially with a non-specific isolated neuro-psychiatric manifestation (motor, cognitive or psychotic). Patients with less severe neurological disability responded better to miglustat therapy.

Keywords